BLOOD 2022: Sustained Clinical Benefits Seen for Combination Daratumumab With Bortezomib, Cyclophosphamide, and Dexamethasone
Daratumumab offers hope for patients with newly diagnosed light chain amyloidosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.